Video

Mutation Analysis in Colorectal Cancer

A majority of colorectal cancer cases are sporadic rather than genetic, which makes it important to caution patients that a mutation analysis is not necessarily performed to look for inherited forms of the disease, but rather, to guide treatment decisions, says Cathy Eng, MD. Additionally, although the goal may be to guide treatment, not all abnormalities found by a gene panel are actionable with a currently available targeted therapy.

It is important to advise patients that it may take 3 to 4 weeks for genetic testing results to be available. It is good to control expectations early, since patients may be anxious to receive their results, states Tanios Bekaii-Saab, MD. It is helpful to let patients know that quite often the results will not immediately change their treatment, adds Saab.

If the genetic test results reveal certain actionable mutations, patients should be provided with information regarding what the findings mean to them. If the results do indicate a familial link to cancer, there should be a separate discussion about the potential need for further genetic testing and counseling, says Saab.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.